期刊文献+

HPLC法测定枸橼酸托法替布片的含量 被引量:3

Content Determination of Active Ingredients in Tofacitinib Citrate Tablets by HPLC
下载PDF
导出
摘要 建立一种液相色谱分析方法,测定枸橼酸托法替布片的含量。采用色谱柱ZORBAX SB-C18 (15 cm×4.6 mm,3μm);乙腈-磷酸盐缓冲液(20︰80)为流动相;检测波长为286 nm;流速为1.0 m L/min;柱温为30℃;采集时间为20 min;进样体积为20μL。结果显示托法替布线性范围为19.965~199.653μg·mL^(-1)(r=0.999);枸橼酸托法替布平均回收率为100.5%,RSD为0.6%。该方法简单准确、重复性好,可用于枸橼酸托法替布片的含量测定。 The high-performance liquid chromatography(HPLC) method was established to determine the content of tofacitinib citrate tablets. Tofacitinib citrate was determined by HPLC as follows: chromatographic column, ZORBAX SB-C18(15 cm×4.6 mm, 3 μm);mobile phase, acetonitrile-phosphate buffer(20︰80);detection wavelength, 286 nm;flow rate, 1.0 mL/min;column temperature, 30 ℃;acquisition time, 20 min;injection volume, 20 μL. The liner range of tofacitinib was 19.965~199.653 μg·mL^(-1)(r=0.999). The average recovery rate of tofacitinib(n=9) was 100.5 % with its RSD value of 0.6 %. The method was simple,accurate and repeatable, which was suitable for the content determination of active ingredients in tofacitinib citrate tablets.
作者 刘永波 Liu Yongbo(R&D center,Sinomune Pharmaceutical Co.,Ltd.,Wuxi 214194,China)
出处 《广东化工》 CAS 2022年第6期192-194,190,共4页 Guangdong Chemical Industry
关键词 HPLC 枸橼酸托法替布 方法学 含量 准确度 HPLC tofacitinib citrate methodology assay accuracy
  • 相关文献

参考文献5

二级参考文献37

  • 1ARNETT FC,EDWORTHY SM, BLOCH DA,et al. The American rheumatism association 1987 revised criteria for classification ofrheumatoid arthritis [ J ]. Arthritis Rheum, 1988,31 ( 3 ) : 315 - 324.
  • 2PERICOLINI E, ALUNNO A, GABRIELLI E, et al. The microbial capsular polysaceharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients [J]. PLoS 0ne,2013,8(1): e53336.
  • 3ZERBINI CA, LOMONTE AB. Tofaeitinib for the treatment of rheumatoid arthritis [J]. Expert Rev Clin lmmunol, 2012,8 (4) : 319 -331.
  • 4CHAPARRO DEL MORAL R, RILLO OL,CASALLA L, et al. Work productivity in rheumatoid arthritis: relationship with clinical and radiological features[ J]. Arthritis, 2012 : 137635.
  • 5MCINNES IB, LIEW FY. Cytokine networks-towards new thera- pies for rheumatoid arthritis [ J ]. Nat Clin Pract Rheumatol, 2005,11(1) :31 -39.
  • 6FLANAGAN ME, BLUMENKOPF TA, BRISSETTE WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection [ J ]. J Med Chem, 2010,53 ( 24 ) : 8468 - 8484.
  • 7GHORESCHI K, JESSON MI, LI X, et al. Modulation of innate and adaptive immune responses by tofaeitinib (CP-690,550) [J]. J lmmunol,2011,186(7) : 4234 -4243.
  • 8TANAKA Y,MAESHIMA Y, YAMAOKA K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis [J]. Ann Rheum Dis ,2012,71 (2) :70 -74.
  • 9KARAMAN MW,HERRGARD S,TREIBER DK, et al. A quan- titative analysis of kinase inhibitor selectivity [ J ]. Nat Biotechnol,2008,26(1) : 127 - 132.
  • 10CHANGELIAN PS,FLANAGAN ME,BALL DJ,et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor[J]. Science.2003.302(5646): 875 -878.

共引文献29

同被引文献34

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部